نتائج البحث - Eric J. Small

تنقيح النتائج
  1. 1
    Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma

    Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma حسب Eric J. Small, Ari David Baron, Robert Bok

    منشور في 1997
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Malignant rhabdoid tumor of the heart in an infant

    Malignant rhabdoid tumor of the heart in an infant حسب Eric J. Small, Beverly Barrett Dahms, Gregory J. Gordon

    منشور في 1985
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102

    A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102 حسب George Philips, Susan Halabi, Ben L. Sanford, Dean F. Bajorin, Eric J. Small

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Cancer and Leukemia Group B 90206

    Cancer and Leukemia Group B 90206 حسب Brian I. Rini, Susan Halabi, John Taylor, Eric J. Small, Richard L. Schilsky

    منشور في 2004
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Germline and Somatic Mutations in Prostate Cancer for the Clinician

    Germline and Somatic Mutations in Prostate Cancer for the Clinician حسب Heather H. Cheng, Alexandra Sokolova, Edward M. Schaeffer, Eric J. Small, Celestia S. Higano

    منشور في 2019
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Combination immunotherapy with prostatic acid phosphatase pulsed antigen‐presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy

    Combination immunotherapy with prostatic acid phosphatase pulsed antigen‐presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer afte... حسب Brian I. Rini, Vivian Weinberg, Lawrence Fong, Shauna Conry, Robert M. Hershberg, Eric J. Small

    منشور في 2006
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer

    Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer حسب Susan Halabi, Nicholas J. Vogelzang, San‐San Ou, Kouros Owzar, Laura Archer, Eric J. Small

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Study

    Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Stud... حسب Charles J. Ryan, Susan Halabi, San-San Ou, Nicholas J. Vogelzang, Philip W. Kantoff, Eric J. Small

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony‐stimulating factor support in patients with hormone‐refractory prostate carcinoma

    A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony‐stimulating factor support in patients with hormone‐refractory prostate carcinoma حسب William Oh, Susan Halabi, William Kevin Kelly, Cary Werner, Paul A. Godley, Nicholas J. Vogelzang, Eric J. Small

    منشور في 2003
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients

    Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients حسب Serena S. Kwek, Vinh Dao, Ritu Roy, Yafei Hou, David Alajajian, Jeffrey P. Simko, Eric J. Small, Lawrence Fong

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma

    A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma حسب Nancy A. Dawson, Mark Conaway, Susan Halabi, Eric P. Winer, Eric J. Small, Diana Lake, Nicholas J. Vogelzang

    منشور في 2000
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480

    The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480 حسب Daniel J. George, Susan Halabi, Timothy F. Shepard, Ben L. Sanford, Nicholas J. Vogelzang, Eric J. Small, Philip W. Kantoff

    منشور في 2005
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy

    Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy حسب Susan Halabi, Andrew J. Armstrong, Oliver Sartor, Johann S. de Bono, Ellen B. Kaplan, Chen‐Yen Lin, Nicole Solomon, Eric J. Small

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate‐resistant prostate cancer

    A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate‐resistant prostate cancer حسب Joel Picus, Susan Halabi, William Kevin Kelly, Nicholas J. Vogelzang, Young E. Whang, Ellen B. Kaplan, Walter M. Stadler, Eric J. Small

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma

    A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma حسب Andrea Harzstark, Eric J. Small, Vivian Weinberg, Janine Sun, Charles J. Ryan, Amy Lin, Lawrence Fong, Dion R. Brocks, Jonathan E. Rosenberg

    منشور في 2011
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer

    Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer حسب Susan Halabi, Chen‐Yen Lin, William K. Kelly, Karim Fizazi, Judd W. Moul, Ellen B. Kaplan, Michael J. Morris, Eric J. Small

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Prospective Trial of the Herbal Supplement PC-SPES in Patients With Progressive Prostate Cancer

    Prospective Trial of the Herbal Supplement PC-SPES in Patients With Progressive Prostate Cancer حسب Eric J. Small, Mark W. Frohlich, Robert Bok, Katsuto Shinohara, Gary D. Grossfeld, Zinovi Rozenblat, Wm. Kevin Kelly, Michele Corry, David Reese

    منشور في 2000
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

    CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion حسب Brian D. Kavanagh, Shaun O’Brien, David S. Lee, Yafei Hou, Vivian Weinberg, Brian I. Rini, James P. Allison, Eric J. Small, Lawrence Fong

    منشور في 2008
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patients

    Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patients حسب Jonathan E. Rosenberg, Vivian Weinberg, William K. Kelly, M. Dror Michaelson, Maha Hussain, George Wilding, Mitchell E. Gross, Douglass Hutcheon, Eric J. Small

    منشور في 2007
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab

    Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab حسب Serena S. Kwek, Jera Lewis, Li Zhang, Vivian Weinberg, Samantha K. Greaney, Andrea Harzstark, Amy Lin, Charles J. Ryan, Eric J. Small, Lawrence Fong

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: